TORONTO, Dec. 13, 2023 Arch Biopartners Inc., , announced today it has submitted a Clinical Trial Application to Health Canada to obtain permission to proceed with a Phase II trial for LSALT.
Arch Biopartners Submits Application to Health Canada to globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
TORONTO, Sept. 22, 2023 Arch Biopartners Inc., , announced that it has submitted applications to the Ministry of Health and local Ethics Committee in Turkey to obtain permission to proceed.
/PRNewswire/ CardioRenal Systems, Inc. announced today that the FDA granted Breakthrough Device Designation for its RenalGuard Therapy® device for the.